دورية أكاديمية

Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens

التفاصيل البيبلوغرافية
العنوان: Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens
المؤلفون: Zamagni, Elena, Dhanasiri, Sujith, Ghale, Arun, Moore, Adam, Roussel, Murielle
المصدر: Leukemia & Lymphoma; Oct 2021, Vol. 62 Issue 10, p2492-2501, 10p
مصطلحات موضوعية: STEM cell transplantation, MULTIPLE myeloma, DIAGNOSIS, TREATMENT effectiveness, LENALIDOMIDE, WATCHFUL waiting
مصطلحات جغرافية: EUROPE
مستخلص: We aimed to compare real-world outcomes, resource use, and costs for patients with newly diagnosed multiple myeloma (NDMM) treated with continuous first-line (1 L) lenalidomide or fixed bortezomib in Europe. We performed a multicenter, retrospective, observational chart review of transplant-ineligible NDMM patients across 7 countries. Of 453 eligible patients, 220 received 1 L lenalidomide-based regimens; 105 (47.7%) received second-line (2 L) treatment, of which 50 (47.6%) received 2 L bortezomib. 233 patients received 1 L bortezomib-based regimens; 142 (60.9%) had 2 L treatment, of which 104 (73.2%) received 2 L lenalidomide. Patients receiving 1 L lenalidomide-based regimens had better progression-free survival than patients receiving 1 L bortezomib-based regimens (p =.002) and a longer time to 2 L or third-line treatment (both p <.05). Total treatment-associated monthly costs for patients receiving 1 L lenalidomide-based regimens (n = 171, €2,268.55) were significantly greater than for 1 L bortezomib-based regimens (n = 188, €1,724.77) (p <.001) over the follow-up period (median, 38.7 months). [ABSTRACT FROM AUTHOR]
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:10428194
DOI:10.1080/10428194.2021.1924369